ALL Metrics
-
Views
-
Downloads
Get PDF
Get XML
Cite
Export
Track
Case Report
Revised

Case Report: Dual nebulised antibiotics among adults with cystic fibrosis and chronic Pseudomonas infection

[version 2; peer review: 3 approved]
PUBLISHED 28 Feb 2018
Author details Author details
OPEN PEER REVIEW
REVIEWER STATUS

Abstract

Pulmonary exacerbations in adults with cystic fibrosis (CF) and chronic Pseudomonas aeruginosa (Psae) infection are usually treated with dual intravenous antibiotics for 14 days, despite the lack of evidence for best practice. Intravenous antibiotics are commonly associated with various systemic adverse effects, including renal failure and ototoxicity. Inhaled antibiotics are less likely to cause systematic adverse effects, yet can achieve airway concentrations well above conventional minimum inhibitory concentrations. Typically one inhaled antibiotic is used at a time, but dual inhaled antibiotics (i.e. concomitant use of two different inhaled antibiotics) may have synergistic effect and achieve better results in the treatment of exacerbations. We presented anecdotal evidence for the use of dual inhaled antibiotics as an acute treatment for exacerbations, in the form of a case report. A female in her early thirties with CF and chronic Psae infection improved her FEV1 by 5% and 2% with two courses of dual inhaled antibiotics to treat exacerbations in 2016. In contrast, her FEV1 changed by 2%, –2%, 0% and 2%, respectively, with four courses of dual intravenous antibiotics in 2016. Baseline FEV1 was similar prior to all six courses of treatments. The greater FEV1 improvements with dual inhaled antibiotics compared to dual intravenous antibiotics suggest the potential role of using dual inhaled antibiotics to treat exacerbations among adults with CF and chronic Psae infection, especially since a greater choice of inhaled anti-pseudomonal antibiotics is now available. A previous study in 1985 has looked at the concomitant administration of inhaled tobramycin and carbenicillin, by reconstituting antibiotics designed for parenteral administration. To our knowledge, this is the first literature to describe the concomitant use of two different antibiotics specifically developed for delivery via the inhaled route.

Keywords

Cystic fibrosis, nebuliser therapy, pulmonary exacerbations, Pseudomonas aeruginosa

Revised Amendments from Version 1

As recommended by Dr Lee, we have:
1. clarified that colomycin 2MU thrice daily was given intravenously alongside intravenous Tazocin
2. clarified the location (home / hospital) for all treatment courses
3. clarified that the subject was also using nebulised dornase alfa throughout all treatment courses
4. provided objective adherence (I-neb data) during the dual nebulised antibiotics courses

As recommended by Drs Frost and Nazareth, we have:
1. mentioned the 2014 randomised cross-over trial of inhaled tobramycin in the introduction
2. clarified that "typically one inhaled antibiotic is used as a time" referred to chronic setting
3. described organisms isolated from her sputum in the prior-year, follow-up year and subsequent year (this was also recommended by Dr Liou)
4. clarified the location (home / hospital) for all treatment courses
5. clarified the use of adjunctive therapies

As recommended by Dr Liou, we have:
1. clarified which treatment courses were specifically for acute exacerbation - the 1st dual nebulised antibiotics course was for acute exacerbation (subject was symptomatic although %FEV1 was relatively stable) and the 3rd intravenous antibiotics course was for acute exacerbation (4% absolute decline in FEV1 from previous although there was no clear symptoms)
2. iterated the sentence in 2nd paragraph of "case report" to clarify the more intensive treatment during the follow-up year
3. provided more detailed results for sputum cultures
4. provided in generic name with first use of trademarked names for nebulised antibiotics, and only using generic name for intravenous antibiotics

We have explained in our response to Dr Liou's comments that we felt adequate history has been provided (especially in terms of age and genotype), and that we have already provided a gold-standard adherence measure in the form of adherence data captured using I-neb (a data logging nebuliser).

See the authors' detailed response to the review by Theodore G. Liou
See the authors' detailed response to the review by Freddy Frost and Dilip Nazareth
See the authors' detailed response to the review by Tim Lee

Introduction

Cystic fibrosis (CF) is a genetic condition whereby ~80% of mortalities are primarily due to lung disease1. People with CF are prone to recurrent respiratory infections (termed ‘pulmonary exacerbations’), which leads to progressive lung damage and respiratory failure2. This is especially so after Pseudomonas aeruginosa (Psae) is acquired3.

Although there is a lack of evidence for best practice in treating exacerbations among adults with CF and chronic Psae infection4, two weeks of dual intravenous antibiotics are generally used for synergistic effect4,5. The European CF Society recommend against using inhaled antibiotics to treat exacerbations, due to concerns that increased mucus plugs during exacerbations may prevent antibiotics from reaching smaller airways5.

There is scant research on using inhaled antibiotics to treat exacerbations. A Cochrane review in 2012 found only four relevant studies, with inadequate sample sizes to demonstrate efficacy6. Subsequently, a randomised cross-over trial among 20 adults with CF and pulmonary exacerbation in 2014 demonstrated longer time to next exacerbation with nebulised compared to intravenous tobramycin (all participants received intravenous colistin as the second antibiotic)7. A large observational study in North America found that ~24% of exacerbations are treated with inhaled antibiotics8. Inhaled antibiotics have several advantages. Systemic adverse effects e.g. allergic reactions, gastrointestinal manifestations, ototoxicity and renal failure are common with intravenous antibiotics9,10 but rare with inhaled antibiotics11. Higher antibiotic concentrations within the airways are achieved via inhaled route, which may be beneficial in overcoming resistance12. Inhaled route also overcomes difficulties associated with venous access.

For long-term suppressive therapy, typically one inhaled antibiotic is used at a time, and someone on multiple inhaled antibiotics would alternate between those antibiotics11. Of the five existing trials looking at inhaled antibiotics for acute exacerbation, only one study with 18 participants concomitantly administed two inhaled antibiotics (tobramycin and carbenicillin)6. Yet dual inhaled antibiotics (i.e. concomitant use of two different inhaled antibiotics) may have synergistic effect, thus achieve better results. We report on an adult with CF and chronic Psae infection who achieved good results when treating exacerbations using dual inhaled antibiotics.

Case report

A Caucasian female in her early thirties with F508del/Class I mutation, pancreatic insufficiency and CF related diabetes also fulfilled the Leeds criteria13 for chronic Psae infection. Only Psae (Liverpool epidemic strain sensitive only to colistin) was cultured from all 12 sputum samples in the previous year. Despite high objective adherence to nebulised dornase alfa 2.5mg once daily and alternating colistin (Promixin®) 1megaunit twice daily/tobramycin (TOBI®) 300mg twice daily (82.9% two years ago, 96.3% in the previous year; measured with an I-neb®), stable BMI around 23.1 and reasonable glycaemic control (HbA1c 47 in month 1 of the follow-up period), there was a trend of declining %FEV1. Her annual best FEV1 was 47%, 44% and 42% over the previous three years. There was no evidence of allergic bronchopulmonary aspergillosis (ABPA) or other CF complications compromising her %FEV1.

In month one, Promixin® was also switched to nebulised Aztreonam (AZLI®) 75mg thrice daily. She had two courses (28 days) of intravenous antibiotics throughout the previous year. She agreed to three-monthly intravenous antibiotics in the follow-up year to try halt the FEV1 decline. She had 14 days of home intravenous piperacillin/tazobactam 4.5g thrice daily and intravenous colistin 2megaunit thrice daily in month one (%FEV1 improved from 38% to 40%), and again in month 4 (%FEV1 declined from 40% to 38%).

She felt less well with increased sputum volume and dyspnoea at the start of month six. Her %FEV1 was 39%. She agreed to try 14 days of concomitant nebulised AZLI® 75mg thrice daily and TOBI® 300mg twice daily at home (nebulised dornase alfa was continued) as treatment for acute exacerbation. She used 69/70 (98.6%) of her nebuliser doses over the 14 days (note that TOBI® twice daily = 4 doses via I-neb® and AZLI® could not be administered via I-neb®). Her %FEV1 improved to 45% at day 7 and 44% at day 14. Her symptoms resolved by day 14.

She felt well but her %FEV1 declined to 39% during her next clinic review at the end of month seven. She went on another 14-day course of home intravenous piperacillin/tazobactam 4.5g thrice daily and intravenous colostin 2megaunit thrice daily as treatment for acute exacerbation. At day 14, her %FEV1 remained 39%. Another 14-day course of home concomitant nebulised AZLI® and TOBI® was started in month 8 (nebulised dornase alfa was continued). She used 66/70 (94.3%) of her nebuliser doses over the 14 days (note that TOBI® twice daily = 4 doses via I-neb® and AZLI® could not be administered via I-neb®). Her %FEV1 improved to 41% at day 7 and day 14, despite developing viral coryzal symptoms at day 12. With 14 days of hospital IV piperacillin/tazobactam 4.5g thrice daily and intravenous tobramycin 480mg once daily in month 11, her %FEV1 improved from 39% at day 1 to 41% at day 14. She received intensive physiotherapy during her in-patient stay in month 11 which may contribute to some of the %FEV1 improvement but received no other adjunctive therapies (e.g. corticosteroid) during all treatment courses. All her inhaled therapies were continued during dual intravenous antibiotic courses.

During the follow-up year, only Psae (Liverpool epidemic strain sensitive only to colistin) was cultured from all eight sputum samples. During the subsequent year, only Psae (Liverpool epidemic strain sensitive only to colistin) was cultured from all nine sputum samples.

Discussion

In this case, %FEV1 improvement following acute treatment of exacerbations with dual inhaled antibiotics at home (mean 3.5% over two courses) was somewhat higher than with dual intravenous antibiotics (mean 0.5% over four courses), despite similar baseline %FEV1 and one of the intravenous antibiotics courses was delivered in hospital. The %FEV1 improvement also occurred despite severe background lung disease (high resolution CT in month eight showed extensive bronchiectasis and baseline %FEV1 was ~40%).

Although she reported symptomatic improvement during her first dual inhaled antibiotics course, we did not formally measure symptomatic responses to treatments with a validated tool. The sample size is too small for null hypothesis significance testing, and regression to the mean is potentially a threat to our results. Our results are nonetheless intriguing and suggest that dual inhaled antibiotics could potentially have a role in treating exacerbations among adults with CF and chronic Psae infection. With the increasing number of inhaled anti-pseudomonal antibiotics available, e.g. nebulised levofloxacin14, different combinations of concomitant inhaled antibiotics can be used in the future for synergistic effect.

Like all medications, there are adverse events associated with inhaled antibiotics. There is a case report of acute respiratory distress syndrome potentially due to inhaled colistin15. However, localised adverse events with inhaled antibiotics are usually mild, e.g. bronchoconstriction which tends to resolve spontaneously within hours or can be controlled by pre-dosing with nebulised bronchodilator11.

High adherence to inhaled therapies probably contributed to the good clinical response from dual inhaled antibiotics observed in this case. Real-world adherence with long-term inhaled antibiotics among adults with CF is only 35–50%16,17. Someone who is already struggling with a single inhaled antibiotic is unlikely to cope with dual inhaled antibiotics, thus may derive less benefit. However, adherence to short-term drug regimen tends to be higher18. Adults with CF might be able to summon adequate self-regulation during a 14-day dual antibiotics course to really focus on their nebuliser use19.

In conclusion, the %FEV1 improvements observed in this case report provide anecdotal evidence that dual inhaled antibiotics could potentially be a treatment option for exacerbations among adults with CF and chronic Psae infection. Given the lack of good quality evidence regarding optimum exacerbations treatments and the theoretical advantages of using inhaled antibiotics, this warrants further investigations.

Consent

Written informed consent for publication of her clinical details was obtained from the patient.

Data availability

No data is associated with this article.

Comments on this article Comments (1)

Version 2
VERSION 2 PUBLISHED 28 Feb 2018
Revised
  • Reader Comment 05 Jul 2018
    Jochen G. Mainz, Jena University Hospital, Germany
    05 Jul 2018
    Reader Comment
    The paper published by Herrmann G, et al. in 2010 gave a clear rationale for combined antibiotic inhalation in CF patients colonized with P. aeruginosa:
    In vitro assessment of three-dimensional ... Continue reading
Author details Author details
Competing interests
Grant information
Copyright
Download
 
Export To
metrics
Views Downloads
F1000Research - -
PubMed Central
Data from PMC are received and updated monthly.
- -
Citations
CITE
how to cite this article
Mann N, Murray S, Hoo ZH et al. Case Report: Dual nebulised antibiotics among adults with cystic fibrosis and chronic Pseudomonas infection [version 2; peer review: 3 approved]. F1000Research 2018, 6:2079 (https://doi.org/10.12688/f1000research.13298.2)
NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.

Open Peer Review

Current Reviewer Status: ?
Key to Reviewer Statuses VIEW
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
Version 2
VERSION 2
PUBLISHED 28 Feb 2018
Revised
Views
7
Cite
Reviewer Report 20 Mar 2018
Theodore G. Liou, Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA 
Approved
VIEWS 7
The case report suggests that dual inhaled antibiotics are feasible as an option for treatment. There were two treatment courses with dual antibiotics using aztreonam and tobramycin on both occasions. One was associated with a 5 percentage point increase in ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Liou TG. Reviewer Report For: Case Report: Dual nebulised antibiotics among adults with cystic fibrosis and chronic Pseudomonas infection [version 2; peer review: 3 approved]. F1000Research 2018, 6:2079 (https://doi.org/10.5256/f1000research.15356.r32187)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
  • Author Response 21 Mar 2018
    Zhe Hui Hoo, Sheffield Adult Cystic Fibrosis Centre, University of Sheffield, Sheffield, S5 7AU, UK
    21 Mar 2018
    Author Response
    We thank Dr Liou for the positive review.
    Competing Interests: No competing interests were disclosed.
COMMENTS ON THIS REPORT
  • Author Response 21 Mar 2018
    Zhe Hui Hoo, Sheffield Adult Cystic Fibrosis Centre, University of Sheffield, Sheffield, S5 7AU, UK
    21 Mar 2018
    Author Response
    We thank Dr Liou for the positive review.
    Competing Interests: No competing interests were disclosed.
Views
5
Cite
Reviewer Report 14 Mar 2018
Freddy Frost, Liverpool Heart and Chest Hospital, Liverpool, UK 
Dilip Nazareth, Liverpool Heart and Chest Hospital, Liverpool, UK 
Approved
VIEWS 5
We are happy with the ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Frost F and Nazareth D. Reviewer Report For: Case Report: Dual nebulised antibiotics among adults with cystic fibrosis and chronic Pseudomonas infection [version 2; peer review: 3 approved]. F1000Research 2018, 6:2079 (https://doi.org/10.5256/f1000research.15356.r31267)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
  • Author Response 15 Mar 2018
    Zhe Hui Hoo, Sheffield Adult Cystic Fibrosis Centre, University of Sheffield, Sheffield, S5 7AU, UK
    15 Mar 2018
    Author Response
    We thank Drs Frost and Nazareth for the positive review.
    Competing Interests: No competing interests were disclosed.
COMMENTS ON THIS REPORT
  • Author Response 15 Mar 2018
    Zhe Hui Hoo, Sheffield Adult Cystic Fibrosis Centre, University of Sheffield, Sheffield, S5 7AU, UK
    15 Mar 2018
    Author Response
    We thank Drs Frost and Nazareth for the positive review.
    Competing Interests: No competing interests were disclosed.
Views
11
Cite
Reviewer Report 01 Mar 2018
Tim Lee, Regional Paediatric Cystic Fibrosis Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK 
Approved
VIEWS 11
I thank the authors for revising the manuscript. My ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Lee T. Reviewer Report For: Case Report: Dual nebulised antibiotics among adults with cystic fibrosis and chronic Pseudomonas infection [version 2; peer review: 3 approved]. F1000Research 2018, 6:2079 (https://doi.org/10.5256/f1000research.15356.r31266)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
  • Author Response 02 Mar 2018
    Zhe Hui Hoo, Sheffield Adult Cystic Fibrosis Centre, University of Sheffield, Sheffield, S5 7AU, UK
    02 Mar 2018
    Author Response
    We thank Dr Lee for the very prompt review.
    Competing Interests: No competing interests were disclosed.
COMMENTS ON THIS REPORT
  • Author Response 02 Mar 2018
    Zhe Hui Hoo, Sheffield Adult Cystic Fibrosis Centre, University of Sheffield, Sheffield, S5 7AU, UK
    02 Mar 2018
    Author Response
    We thank Dr Lee for the very prompt review.
    Competing Interests: No competing interests were disclosed.
Version 1
VERSION 1
PUBLISHED 01 Dec 2017
Views
12
Cite
Reviewer Report 08 Feb 2018
Theodore G. Liou, Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA 
Approved with Reservations
VIEWS 12
This is a case report of a patient with CF during a 6 month period during which she was treated with multiple antibiotics in several regimens that seemed to differ with each treatment episode.
 
The introduction is ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Liou TG. Reviewer Report For: Case Report: Dual nebulised antibiotics among adults with cystic fibrosis and chronic Pseudomonas infection [version 2; peer review: 3 approved]. F1000Research 2018, 6:2079 (https://doi.org/10.5256/f1000research.14431.r29543)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
  • Author Response 09 Feb 2018
    Zhe Hui Hoo, Sheffield Adult Cystic Fibrosis Centre, University of Sheffield, Sheffield, S5 7AU, UK
    09 Feb 2018
    Author Response
    We thank Dr Liou for the review and we will iterate the case report taking into account the comments.

    In Sheffield whereby we only provide care for around 200 adults with ... Continue reading
COMMENTS ON THIS REPORT
  • Author Response 09 Feb 2018
    Zhe Hui Hoo, Sheffield Adult Cystic Fibrosis Centre, University of Sheffield, Sheffield, S5 7AU, UK
    09 Feb 2018
    Author Response
    We thank Dr Liou for the review and we will iterate the case report taking into account the comments.

    In Sheffield whereby we only provide care for around 200 adults with ... Continue reading
Views
14
Cite
Reviewer Report 30 Jan 2018
Freddy Frost, Liverpool Heart and Chest Hospital, Liverpool, UK 
Dilip Nazareth, Liverpool Heart and Chest Hospital, Liverpool, UK 
Approved with Reservations
VIEWS 14
Mann et al report an interesting case demonstrating that inhaled antibiotics may be useful for the treatment of acute pulmonary exacerbations in CF. The authors accurately describe the background and much of the evidence relating to the use of inhaled antibiotics in ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Frost F and Nazareth D. Reviewer Report For: Case Report: Dual nebulised antibiotics among adults with cystic fibrosis and chronic Pseudomonas infection [version 2; peer review: 3 approved]. F1000Research 2018, 6:2079 (https://doi.org/10.5256/f1000research.14431.r30297)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
  • Author Response 30 Jan 2018
    Zhe Hui Hoo, Sheffield Adult Cystic Fibrosis Centre, University of Sheffield, Sheffield, S5 7AU, UK
    30 Jan 2018
    Author Response
    We thank Drs Frost and Nazareth for the review and very useful comments which will guide our revision of the case report.

    We will include 2014 pilot study of nebulised vs IV tobramycin in ... Continue reading
COMMENTS ON THIS REPORT
  • Author Response 30 Jan 2018
    Zhe Hui Hoo, Sheffield Adult Cystic Fibrosis Centre, University of Sheffield, Sheffield, S5 7AU, UK
    30 Jan 2018
    Author Response
    We thank Drs Frost and Nazareth for the review and very useful comments which will guide our revision of the case report.

    We will include 2014 pilot study of nebulised vs IV tobramycin in ... Continue reading
Views
22
Cite
Reviewer Report 04 Jan 2018
Tim Lee, Regional Paediatric Cystic Fibrosis Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK 
Approved with Reservations
VIEWS 22
This is a useful case report highlighting the potential for treating certain pulmonary exacerbations in people with cystic fibrosis with inhaled antibiotics. The background is well written. References are appropriate and balanced.

The case is well described ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Lee T. Reviewer Report For: Case Report: Dual nebulised antibiotics among adults with cystic fibrosis and chronic Pseudomonas infection [version 2; peer review: 3 approved]. F1000Research 2018, 6:2079 (https://doi.org/10.5256/f1000research.14431.r29445)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
  • Author Response 04 Jan 2018
    Zhe Hui Hoo, Sheffield Adult Cystic Fibrosis Centre, University of Sheffield, Sheffield, S5 7AU, UK
    04 Jan 2018
    Author Response
    We thank Dr Lee for the review and very useful comments which will guide our revision of the case report.

    We will clarify in Paragraph 2 (and 4) of the "Case ... Continue reading
COMMENTS ON THIS REPORT
  • Author Response 04 Jan 2018
    Zhe Hui Hoo, Sheffield Adult Cystic Fibrosis Centre, University of Sheffield, Sheffield, S5 7AU, UK
    04 Jan 2018
    Author Response
    We thank Dr Lee for the review and very useful comments which will guide our revision of the case report.

    We will clarify in Paragraph 2 (and 4) of the "Case ... Continue reading

Comments on this article Comments (1)

Version 2
VERSION 2 PUBLISHED 28 Feb 2018
Revised
  • Reader Comment 05 Jul 2018
    Jochen G. Mainz, Jena University Hospital, Germany
    05 Jul 2018
    Reader Comment
    The paper published by Herrmann G, et al. in 2010 gave a clear rationale for combined antibiotic inhalation in CF patients colonized with P. aeruginosa:
    In vitro assessment of three-dimensional ... Continue reading
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Sign In
If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

The email address should be the one you originally registered with F1000.

Email address not valid, please try again

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Google account password, please click here.

You registered with F1000 via Facebook, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Facebook account password, please click here.

Code not correct, please try again
Email us for further assistance.
Server error, please try again.